Here are 5 ASX Halloween Stocks!
The Reject Shop (ASX:TRS)
The Reject Shop is one of Australia's most notable retail chains - a classic discount variety store selling various goods, including for Halloween. Investors would be surprised that companies' busiest times of the year can be outside the Black Friday/Christmas season. Dusk Group…
Metal recovery may never be the same again if MTM Critical Metals (ASX:MTM) has its way. Metal refinery will become increasingly important to meet the world's need for critical metals as deposits become more scarce and more difficult to discover and bring into production. But current methods have significant time and monetary costs which need…
Imugene (ASX:IMU) is still valued at over $400m, in spite of being valued at over $2bn back in 2021 and having had a rollercoaster 12 months.
Imugene (ASX:IMU) share price chart, log scale (Source: TradingView)
Even though it has assets that have passed Phase 2 trials, it has never gotten to Phase 3. Yet it has $93.1m…
Do oil and gas stocks have a future...at all? And if they do, what does it look like? Evidently, it won't be anything like the previous century as the world turns to renewable energy. It is not quite dead yet - after all, the world consumed 100 million barrels per day (mb/d) according to the…
The revenue model of Betting stocks is different to any other industry and can confuse even the most seasoned analysts. In this article, we recap just how they work so that investors can better understand their business models.
What are the Best ASX Stocks to invest in right now?
Check our buy/sell tips
[sg_popup id="23914" event="click"][/sg_popup]
How do…
On 6 September 2024 the stock of the mineral explorer Osmond Resources (ASX: OSM) started coming back to life. Before then it was bumping along at around 7 cents per share. Suddenly investor interest in took off, after the company announced it was buying into the Orion EU Critical Minerals Project in Spain. Osmond stock…
One time wealth management giant AMP (ASX: AMP) has endured a massive fall from grace over the years. There is an argument to be made that now is turnaround time, since it now has a banking brand and wealth management platform, which are both performing well. And shares are up over 50% since November last…
If you thought reporting season was done and dusted for all companies, you'd be wrong - because some companies use an October to September financial year. And these companies will be reporting in the next few weeks. Most use a July to June financial year, but can use whatever 12 month period they like as…
Island Pharmaceuticals (ASX:ILA) is one of the few (if not the only) ASX-listed Biotechs that is focused on mosquito diseases, primarily Dengue fever. Mosquito diseases, such as Dengue, are expensive to treat and are expected to proliferate due to climate change and the consequential boom in the mosquito population. But maybe Island Pharmaceuticals can help.
Introduction…
Investors should expect to see more ASX biotechs focus on Asia in the years ahead. And there are good reasons why.
For many companies, the golden market has been the USA, given its population and stringent regulator the Food and Drug Administration (FDA). If a company can commercialise a drug in the USA, it can succeed…
